推薦產品
藥物控制
USDEA Schedule IV
溶解度
ethanol: soluble
起源
Schering Plough
儲存溫度
2-8°C
SMILES 字串
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
InChI
1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
InChI 密鑰
OFZCIYFFPZCNJE-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
Carisoprodol (N-isopropyl-2-methyl-2-propyl-l,3-propanediol dicarbamate) is a dicarbamate that is structurally similar to mephenesin and meprobamate. It functions as a skeletal muscle relaxant and has analgesic properties. Although it does not have an effect on behavior, it inhibits reticular formation. The area associated with pain perception in the CNS is affected by carisoprodol for its analgesic activity.
Carisoprodol is actively metabolized to meprobamate, a depressant of the CNS having sedative hypnotic.
Carisoprodol is actively metabolized to meprobamate, a depressant of the CNS having sedative hypnotic.
應用
Carisoprodol has been used as a standard for quantitative determination of carisoprodol in tablets using high-performance thin-layer chromatography. It has also been used to study the effect of pharmacological agents on the muscles of dystrophin-deficient mdx5Cv mice.
生化／生理作用
Metabolite of meprobamate that is a skeletal muscle relaxant, reduces muscle spasm by depression of brainstem neurons.
特點和優勢
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
J G Bramness et al.
Clinical pharmacology and therapeutics, 91(3), 438-441 (2012-02-10)
Carisoprodol, a centrally acting muscle relaxant indicated for acute lower back pain, has been available in Europe and the United States since 1959. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market
James P Zacny et al.
Drug and alcohol dependence, 120(1-3), 229-232 (2011-08-16)
Some chronic pain patients on long-term opioid therapy also take centrally active skeletal muscle relaxants. One of those muscle relaxants is carisoprodol, a drug that is abused and capable of producing impairment. It would be of relevance to characterize the
Laxmaiah Manchikanti et al.
Pain physician, 16(1), E1-E13 (2013-01-24)
Reports of chronic pain and associated opioid use, abuse, and fatalities continue to increase at an alarming rate, not only in the United States but also across the globe. In light of the many resultant fatalities, multiple authors and authorities
Jennifer A Fass
The Annals of pharmacotherapy, 44(12), 1962-1967 (2010-11-11)
To review the current legal status and patterns of abuse of carisoprodol. A literature search was conducted through MEDLINE (1950-August 2010), PubMed (1966-August 2010), EMBASE (1966-August 2010), and International Pharmaceutical Abstracts (1970-August 2010) using the search terms carisoprodol and abuse.
Michael B Gatch et al.
Drug and alcohol dependence, 123(1-3), 29-34 (2011-11-08)
Carisoprodol is a muscle relaxant that acts at the GABA(A) receptor. Concerns about the abuse liability of carisoprodol are increasing, but evidence that carisoprodol produces tolerance and a significant withdrawal syndrome has yet to be established. The purpose of the
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務